Treatment of Osteogenesis Imperfecta with the Bisphosphonate Olpadronate (dimethylaminohydroxypropylidene Bisphosphonate)
Overview
Affiliations
Unlabelled: Osteoporosis is an important feature of osteogenesis imperfecta (OI). So far, no effective medical treatment is available. We treated three boys with severe OI type III and vertebral deformities for 5-7 years with continuous oral administration of the bisphosphonate, olpadronate. Treatment resulted in a decreased number of bone fractures, an increased calcification of the long bones and an amelioration of vertebral shape. No side-effects were encountered.
Conclusion: These preliminary but long-term observations suggest that the bisphosphonate olpadronate may be a useful treatment for patients with OI and vertebral fractures. Bisphosphonates may be promising drugs for children with OI.
Zhang B, Li R, Wang W, Zhou X, Luo B, Zhu Z J Orthop Surg Res. 2021; 16(1):359.
PMID: 34078411 PMC: 8170984. DOI: 10.1186/s13018-021-02495-2.
Current and emerging treatments for the management of osteogenesis imperfecta.
Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G Ther Clin Risk Manag. 2010; 6:367-81.
PMID: 20856683 PMC: 2940745. DOI: 10.2147/tcrm.s5932.
Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.
Rao S, Evans K, Oberbauer A, Martin R J Biomech. 2008; 41(16):3371-6.
PMID: 19022450 PMC: 2633864. DOI: 10.1016/j.jbiomech.2008.09.028.
Kok D, Sakkers R, Janse A, Pruijs H, Verbout A, Castelein R Eur J Pediatr. 2007; 166(11):1155-61.
PMID: 17308899 DOI: 10.1007/s00431-006-0399-2.
Thornton J, Ashcroft D, Mughal M, Elliott R, ONeill T, Symmons D Arch Dis Child. 2006; 91(9):753-61.
PMID: 16690698 PMC: 2082926. DOI: 10.1136/adc.2006.093997.